Effects of idiotypic human anti-mouse antibody against in vitro binding and antitumor activity of a monoclonal antibody-drug conjugate

Hepato-Gastroenterology

Volumn 50, Issue 50, 2003, Pages 380-384

  Otsuji, Eigo ^a   Tsuruta, Hiroshi ^a   Toma, Atsushi ^a   Kobayashi, Shinichiro ^a   Okamoto, Kazuma ^a   Yata, Yoshihiro ^a   Yamagishi, Hisakazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Human anti mouse antibody; Monoclonal antibody; Neocarzinostatin; Targeting chemotherapy

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; HUMAN ANTI MOUSE ANTIBODY; IDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ZINOSTATIN;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER THERAPY; CARCINOMA CELL; COLON CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; BINDING SITES, ANTIBODY; COLONIC NEOPLASMS; HUMANS; IMMUNOCONJUGATES; MICE; TUMOR CELLS, CULTURED; ZINOSTATIN;

EID: 0037349134     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Dillman R, Shawler D, Dillman J, Royston R: Therapy of chronic lymphocytic leukemia and cutaneous lymphoma with T101 monoclonal antibody. J Clin Oncol 1984; 2:881-891.
2. Shawler DL, Bartholomew RM, Smith ML, Dillman RO: Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985; 135:1530-1535.
3. Pimm MV, Perkins AC, Armitage NC, Baldwin RW: The characteristics of blood-borne radiolabels and the effect of anti-mouse IgG antibodies on localization of radiolabeled monoclonal antibody in cancer patients. J Nucl Med 1985; 26:11-23.
4. Courtenay-Luck NS, Epenetos AA, Moore R, Larche M, Pectasides D, Dhokia B, Ritte MA: Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 1986; 46:6489-6493.
5. Haspel MV, McCabe RP, Pomato N, Janesch NJ, Knowlton JV, Peters LC, Hoover HC, Hanna MG: Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients. Cancer Res 1985; 45:3951-3961.
6. Spiegelberg HL, Weigle WO: The catabolism of homologous and heterologous 7s gamma globulin fragments. J Exp Med 1965; 121:323-338.
7. Hosono M, Endo K, Sakahara H, Watanabe Y, Saga T, Nakai T, Kawai C, Matsumori A, Yamada T Watanabe T, Konishi J: Human/mouse chimeric antibodies show low reactivity with human anti-murine antibodies (HAMA). Br J Cancer 1992; 65:197-200.
8. Takahashi T, Yamaguchi T, Kitamura K, Noguchi A, Honda M, Otsuji E: Follow-up study of patients treated with monoclonal antibody-drug conjugate: Report of 77 cases with colorectal cancer. Jpn J Cancer Res 1993; 84:976-981.
9. Noguchi P, Wallace R, Johnson J, Earley EM, O'Brien S, Ferrone S, Pellegrino MA, Milstien J, Needy C, Browne W, Petricciani J: Characterization of WiDr: a human colon carcinoma cell line. In Vitro 1979; 15:401-408.
10. Otsuji E, Yamaguchi T, Yamaoka N, Koyama K, Imanishi J, Yamaoka N, Takahashi T: Increased anti-tumor effect of neocarzinostatin conjugated to monoclonal antibody A7 on human pancreatic carcinoma grafted in the nude mice. Antibody Immunoconj Radiopharm 1993; 6:177-183.
11. Otsuji E, Yamaguchi T, Yamaguchi N, Koyama K, Imanishi J, Yamaoka N, Takahashi T: Expression of the cell surface antigen detected by the monoclonal antibody A7 in pancreatic carcinoma cell lines. Surg Today 1992; 22:351-356.
12. Hunter WM, Greenwood FC: Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 1962; 194:495-496.
13. Schroff RW, Foon A, Beatty SM, Oldham RK, Morgan AC Jr: Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985; 45:879-885.
14. Tjandra JJ, Ramadi L, McKenzie IFC: Development of human anti-murine antibody (HAMA) response in patients. Immunol Cell Biol 1990; 68:367-376.
15. 131I-labelled human IgM monoclonal antibody 16.88 in advanced colorectal cancer patients. Eur J Cancer 1991; 27:1430-1436.
16. Haisma HJ, Pinedo H M, Kessel MAP, van Muijen M, Roos JC, Plaizier M, Martens HJM, DeJager R, Boven E: Human IgM monoclonal antibody 16.88: pharmacokinetics and immunogenicity in colorectal cancer patients. J Natl Cancer Inst 1991; 83:1813-1819.
17. Phillips J, Sikora K, Watson JV: Localization of glioma by human monoclonal antibody. Lancet 1982; 2B:1214-1215.
18. Hoogenboom HR, Winter G: By-passing immunization. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J Mol Biol 1992; 227:381-388.
19. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G: Replacing the complementary-determining regions in a human antibody with those from a mouse. Nature 1986; 321:522-525.
20. Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, Waldmann H: Humanized monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992; 340:748-752.
21. Legouffe E, Liautard J, Gaillard JP, Rossi JF, Wijdedes J, Bataille R, Klein B, Brochier J: Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin Exp Immunol 1994; 98:323-329.
22. Gruber R, van Haarlem LJ, Warnaar SO, Holz E, Riethmuller G: The human antinouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A. Cancer Res 2000; 60:1921-1926.
23. Hertel A, Baum R: Influence of human anti-murine antibodies on in vitro assays in ovarian cancer patients. Hybridoma 1993; 12:571-576.
24. Yamaguchi T, Tsurumi H, Kitamura K, Otsuji E, Miyagaki T, Kotani T, Takahashi T: Production, binding and cytotoxicity of human/mouse chimeric monoclonal antibody-neocarzinostatin conjugate. Jpn J Cancer Res 1993; 84:1190-1194.
25. Khazaeli MB, Saleh MN, Liu TP, Meredith RF, Wheeler RH, Baker TS, King D, Secher D, Allen L, Rogers K, Colcher D, Schlom J, Shochat D, LoBuglio AF: Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans. Cancer Res 1991; 51:5461-5466.
26. Saleh MN, Khazaeli MB, Wheeler RH, Allen L, Tilden AB, Grizzle W, Reisfeld RA, Yu AL, Gillies SD, LoBuglio AF: Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibod Hybridomas 1992; 3:19-24.
27. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaell MB, Kelly S, Tepper MA, Grasela D, Buzdar A, Valero V, Booser D, Whealin H, Collins TJ, Pursley JM, Hortobagyi G: Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res 1995; 55:3060-3067.